Page 178 - Read Online

Battaglin et al. J Cancer Metastasis Treat 2018;4:12 I http://dx.doi.org/10.20517/2394-4722.2018.04 Page 23 of 25

Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA Jr, Trusolino L,
Velculescu VE. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 2015;526:263-7.
138 Lee MS, Kopetz S. Current and future approaches to target the epidermal growth factor receptor and its downstream signaling in
metastatic colorectal cancer. Clin Colorectal Cancer 2015;14:203-18.
139 Cremolini C, Morano F, Moretto R, Berenato R, Tamborini E, Perrone F, Rossini D, Gloghini A, Busico A, Zucchelli G, Baratelli C,
Tamburini E, Capone I, Volpi C, Milione M, Di Maio M, Fontanini G, De Braud FG, Falcone A, Pietrantonio F. Dissecting primary
resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): a case-control study. J Clin Oncol 2017;35:abstr
11508.
140 Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, Valtorta
E, Truini M, Jessop NA, Robinson HE, Hong TS, Mino-Kenudson M, Di Nicolantonio F, Thabet A, Sartore-Bianchi A, Siena S, Iafrate
AJ, Bardelli A, Corcoran RB. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov
2016;6:147-53.
141 Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from
heterogeneity to convergent evolution. Cancer Discov 2014;4:1269-80.
142 Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, Salido M, Gallen M, Marsters S, Tsai SP, Minoche A, Seshagiri
S, Serrano S, Himmelbauer H, Bellmunt J, Rovira A, Settleman J, Bosch F, Albanell J. Identification of a mutation in the extracellular
domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012;18:221-3.
143 Esposito C, Rachiglio AM, La Porta ML, Sacco A, Roma C, Iannaccone A, Tatangelo F, Forgione L, Pasquale R, Barbaro A, Botti G,
Ciardiello F, Normanno N. The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before
exposure to EGFR monoclonal antibodies. Cancer Biol Ther 2013;14:1143-6.
144 Voigt M, Braig F, Göthel M, Schulte A, Lamszus K, Bokemeyer C, Binder M. Functional dissection of the epidermal growth factor
receptor epitopes targeted by panitumumab and cetuximab. Neoplasia 2012;14:1023-31.
145 Arena S, Bellosillo B, Siravegna G, Martínez A, Cañadas I, Lazzari L, Ferruz N, Russo M, Misale S, González I, Iglesias M, Gavilan
E, Corti G, Hobor S, Crisafulli G, Salido M, Sánchez J, Dalmases A, Bellmunt J, De Fabritiis G, Rovira A, Di Nicolantonio F, Albanell
J, Bardelli A, Montagut C. Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer. Clin
Cancer Res 2015;21:2157-66.
146 Price TJ, Newhall K, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AV, Thomas A, Tjulandin S, Boedigheimer M, Zhang K, Sidhu
R, Murugappan S. Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: panitumumab
(pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). J Clin Oncol
2015;33:abstr740.
147 Arena S, Siravegna G, Mussolin B, Kearns JD, Wolf BB, Misale S, Lazzari L, Bertotti A, Trusolino L, Adjei AA, Montagut C, Di
Nicolantonio F, Nering R, Bardelli A. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers
harboring EGFR extracellular domain mutations. Sci Transl Med 2016;8:324ra314.
148 Dienstmann R, Patnaik A, Garcia-Carbonero R, Cervantes A, Benavent M, Roselló S, Tops BB, van der Post RS, Argilés G, Skartved
NJ, Hansen UH, Hald R, Pedersen MW, Kragh M, Horak ID, Braun S, Van Cutsem E, Tolcher AW, Tabernero J. Safety and activity of
the first-in-class Sym004 Anti-EGFR antibody mixture in patients with refractory colorectal cancer. Cancer Discov 2015;5:598-609.
149 Cidon EU, Alonso P, Masters B. Markers of response to antiangiogenic therapies in colorectal cancer: where are we now and what
should be next? Clin Med Insights Oncol 2016;10:41-55.
150 Bates DO, Catalano PJ, Symonds KE, Varey AH, Ramani P, O’Dwyer PJ, Giantonio BJ, Meropol NJ, Benson AB, Harper SJ.
Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with
bevacizumab. Clin Cancer Res 2012;18:6384-91.
151 Carbone C, Piro G, Simionato F, Ligorio F, Cremolini C, Loupakis F, Alì G, Rossini D, Merz V, Santoro R, Zecchetto C, Zanotto M,
Di Nicolantonio F, Bardelli A, Fontanini G, Tortora G, Melisi D. Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal
cancer patients. Clin Cancer Res 2017;23:4312-22.
152 Paiva TF Jr, de Jesus VH, Marques RA, da Costa AA, de Macedo MP, Peresi PM, Damascena A, Rossi BM, Begnami MD, de Lima VC.
Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival.
BMC Cancer 2015;15:643.
153 US National Library of Medicine. A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer. Identifier: NCT
NCT03035253. Available from: https://clinicaltrials.gov/ct2/show/NCT03035253?term=bispecific+oncomed&rank=1 [Last accessed on
17 Jan 2018]
154 Zuurbier L, Rahman A, Cordes M, Scheick J, Wong TJ, Rustenburg F, Joseph JC, Dynoodt P, Casey R, Drillenburg P, Gerhards M,
Barat A, Klinger R, Fender B, O’Connor DP, Betge J, Ebert MP, Gaiser T, Prehn JHM, Griffioen AW, van Grieken NCT, Ylstra B, Byrne
AT, van der Flier LG, Gallagher WM, Postel R. Apelin: a putative novel predictive biomarker for bevacizumab response in colorectal
cancer. Oncotarget 2017;8:42949-61.
155 Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Yoshino T,
Goldberg RM, Sargent DJ, Wagner A, Laurent D, Teufel M, Jeffers M, Grothey A, Van Cutsem E. Analysis of circulating DNA and
protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a
retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 2015;16:937-48.
156 Wirapati P, Pomella V, Vandenbosch B, Kerr P, Maiello E, Jeffery GM, Curca ROD, Karthaus M, Bridgewater JA, Mihailov AC, Kiss I,
Merino S, McKendrick JJ, Saridaki Z, Sagaert XJA, Tejpar S. Velour trial biomarkers update: impact of RAS, BRAF, and sidedness on